KIR3DL2 Receptors

A KIR receptor that has specificity for HLA-A3 ANTIGEN. It is an inhibitory receptor that contains D0, D1, and D2 extracellular immunoglobulin-like domains and a long cytoplasmic tail.

Also Known As:

Receptors, KIR3DL2; CD158k Antigen; KIR3DL2 Receptor; Killer Cell Immunoglobulin-Like Receptor 3DL2; p140-KIR3DL2 Inhibitory Receptor; Antigen, CD158k; Inhibitory Receptor, p140-KIR3DL2; Killer Cell Immunoglobulin Like Receptor 3DL2; Receptor, KIR3DL2; Receptor, p140-KIR3DL2 Inhibitory; p140 KIR3DL2 Inhibitory Receptor; Antigens, CD158k; CD158k Antigens

Networked: 6 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - Immunologic Receptors: 9
        Natural Killer Cell Receptors: 407
        KIR Receptors: 632
        KIR3DL2 Receptors: 6
        human KIR3DL2 protein

Experts

1.	Bagot, Martine: 3 articles (08/2018 - 10/2014)
2.	Bensussan, Armand: 2 articles (09/2015 - 10/2014)
3.	Marie-Cardine, Anne: 2 articles (09/2015 - 10/2014)
4.	Sicard, Hélène: 2 articles (09/2015 - 10/2014)
5.	Wang, Qi: 2 articles (01/2011 - 06/2009)
6.	Darcy, Phil K: 1 article (08/2018)
7.	Neeson, Paul: 1 article (08/2018)
8.	Prince, H Miles: 1 article (08/2018)
9.	Van Der Weyden, Carrie: 1 article (08/2018)
10.	Bonnafous, Cécile: 1 article (09/2015)

Related Diseases

1.	Pre-Eclampsia (Preeclampsia) 06/02/2009 - "[The study of killer cell immunoglobulin-like receptor 3DL2 gene polymorphisms and pre-eclampsia]." 01/01/2011 - "We evaluated if killer cell immunoglobulin-like receptor 3DL2 gene (KIR3DL2) polymorphisms are a key factor in the development of preeclampsia. " 01/01/2011 - "Genetic polymorphisms of killer cell immunoglobulin-like receptor 3DL2 in preeclampsia."
2.	Neoplasms (Cancer) 09/01/2015 - "An antibody-based CTCL-specific immunotherapy targeting the KIR3DL2 receptor expressed by the tumor cells in CTCL is currently under development and has shown encouraging results in pre-clinical studies."
3.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 08/01/2018 - "Areas covered: In this review, we examine data demonstrating the tissue specificity of KIR3DL2 receptor, which is highly expressed on the malignant cells in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome. " 10/01/2014 - "Cutaneous T-cell lymphoma cells express the natural killer receptor KIR3DL2 (CD158k) used as a tumor marker. "
4.	Mycosis Fungoides 08/01/2018 - "Areas covered: In this review, we examine data demonstrating the tissue specificity of KIR3DL2 receptor, which is highly expressed on the malignant cells in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome. "
5.	Infections 02/15/2015 - "We proposed that the killer cell Ig-like receptor KIR3DL2 binding more strongly to HLA-B27 (B27) β2-microglobulin free H chain (FHC) dimers than other HLA-class I molecules regulates lymphocyte function in arthritis and infection. "

Related Drugs and Biologics

1.	HLA-B27 Antigen (HLA B27 Antigen)
2.	Tumor Biomarkers (Tumor Markers)

Related Therapies and Procedures

1.	Immunotherapy